Who are telomerase peptide vaccine GV1001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etakridin, HU-014, allovectin-7/dacarbazine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/telomerase-peptide-vaccine-gv1001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

telomerase peptide vaccine GV1001 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

telomerase peptide vaccine GV1001 (telomerase peptide vaccine GV1001) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Telomerase Oncology Biologic Live · refreshed every 30 min

Target snapshot

telomerase peptide vaccine GV1001 (telomerase peptide vaccine GV1001) — Royal Liverpool University Hospital. GV1001 works by stimulating an immune response against telomerase, a protein often overexpressed in cancer cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
telomerase peptide vaccine GV1001 TARGET	telomerase peptide vaccine GV1001	Royal Liverpool University Hospital	phase 3		Telomerase
Etakridin	ETHACRIDINE		marketed	ethacridine	Telomerase reverse transcriptase, Reverse transcriptase, Reverse transcriptase/RNaseH
HU-014	HU-014	Huons Co., Ltd.	phase 3	Telomerase inhibitor	Telomerase
allovectin-7/dacarbazine	allovectin-7/dacarbazine	Vical	phase 3	DNA vaccine, chemotherapy	Telomerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). telomerase peptide vaccine GV1001 — Competitive Intelligence Brief. https://druglandscape.com/ci/telomerase-peptide-vaccine-gv1001. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab